Schering Targets Mylan Over Vytorin ANDA

Law360, New York (December 22, 2009, 2:20 PM EST) -- Merck & Co. Inc. subsidiary Schering Corp. has ignited the latest round of litigation over its cholesterol drug Vytorin, hitting Mylan Pharmaceuticals Inc. with a patent infringement suit following the rival drugmaker's filing of an abbreviated new drug application for a generic version of the drug.

In a complaint lodged Friday in the U.S. District Court for the Northern District of West Virginia, Schering claims that Mylan submitted its ANDA to the U.S. Food and Drug Administration seeking approval to produce ezetimibe and simvastatin tablets —...
To view the full article, register now.